New York, Feb 21, 2026, 13:15 EST — The market is closed.
- Shares of Eli Lilly slipped 1.3% Friday, missing out on the broader market’s gains.
- Tougher scrutiny of compounded GLP-1 “copycat” weight-loss drugs is on investors’ minds.
- Lilly’s CFO is set to speak March 2. Investors are also eyeing an FDA decision, likely in April, on the company’s obesity pill.
Eli Lilly and Co closed out Friday at $1,009.52, slipping 1.34%.
U.S. markets are closed for the weekend, leaving the stock facing Monday with its usual catalysts—and a growing question mark: decisions by regulators and courts on lower-cost, pharmacy-compounded obesity drugs. That verdict could upend who’s buying and what they’re willing to pay.
Lilly’s impressive expansion, all thanks to its GLP-1 drugs that suppress appetite and reduce blood sugar, has investors glued to every move — there’s little tolerance for missteps here. Earlier this month, the company projected 2026 adjusted earnings per share at $33.50 to $35, and put sales between $80 billion and $83 billion, numbers that landed ahead of Wall Street’s forecasts.
Lilly shares slipped Friday, bucking the trend as the S&P 500 advanced 0.69% and the Dow added 0.47%, according to MarketWatch data. The stock is currently trading about 11% below its Jan. 8 high of $1,133.95. Around 3.2 million Lilly shares changed hands—matching its 50-day average volume.
Just a day ago, Reuters reported that telehealth firm Hims & Hers ran into immediate backlash after it launched a $49 compounded oral semaglutide pill, only to pull back once FDA Commissioner Marty Makary labeled the products “illegal copycats.” BMO Capital Markets’ Evan Seigerman, who covers Lilly, put it plainly: “Lilly and Novo are always going to be able to make their product more efficiently.” Reuters
Compounding pharmacies are allowed to make custom drugs within strict guidelines, usually when a patient can’t get an approved version in the needed dose. The FDA has flagged a rise in compounded GLP-1 drugs that haven’t been approved, pointing to misleading labels and warning that it can’t ensure these products’ quality, safety, or effectiveness.
In a separate disclosure dated Feb. 19, Lilly’s EVP and chief people officer Eric Dozier reported gifting 481 shares at $0, according to a regulatory filing. Following the transaction, Dozier’s direct ownership stands at roughly 14,455 shares.
Lilly’s investor calendar shows CFO Lucas Montarce set for a 3:10 p.m. ET fireside chat on March 2 at TD Cowen’s annual health care conference. The next earnings event lands April 30, with first-quarter results on deck.
Lilly’s bigger play goes beyond next week: it’s chasing a shift from injections to pills for weight loss. According to Reuters, the company has amassed $1.5 billion worth of “pre-launch inventory” of its oral obesity candidate, orforglipron, as it waits for the FDA’s call—expected in April. Meanwhile, Novo Nordisk’s new daily weight-loss pill is already seeing traction, pulling in over 26,000 prescriptions in its second full week on the U.S. market, IQVIA data via an analyst shows. Reuters
As Monday’s session gets underway, traders will be watching for any new developments in the legal and regulatory battle surrounding compounded GLP-1s. They’ll also be tracking whether branded drugmakers continue trimming out-of-pocket costs to try to undercut the draw of cheaper copies.
Still, the risks remain. If prices drop faster, payers dig in harder, or “compounded” users take longer to move over to branded drugs, Lilly’s growth assumptions—which are carrying plenty of weight in the stock’s valuation—could come under real strain.
March 2 is circled as the next key date. Investors want Montarce to shed more light on pricing, supply and demand—and to hear how management is sizing up the company’s path toward an FDA call on orforglipron in April.
